Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis

Authors: Xin Yin, Jadwiga Truty, Roger Lawrence, Scott C Johns, R Sathish Srinivasan, Tracy M Handel, Mark M Fuster

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Lymph node metastasis constitutes a key event in tumor progression. The molecular control of this process is poorly understood. Heparan sulfate is a linear polysaccharide consisting of unique sulfate-modified disaccharide repeats that allow the glycan to bind a variety of proteins, including chemokines. While some chemokines may drive lymphatic trafficking of tumor cells, the functional and genetic importance of heparan sulfate as a possible mediator of chemokine actions in lymphatic metastasis has not been reported.

Results

We applied a loss-of-function genetic approach employing lymphatic endothelial conditional mutations in heparan sulfate biosynthesis to study the effects on tumor-lymphatic trafficking and lymph node metastasis. Lymphatic endothelial deficiency in N-deacetylase/N-sulfotransferase-1 (Ndst1), a key enzyme involved in sulfating nascent heparan sulfate chains, resulted in altered lymph node metastasis in tumor-bearing gene targeted mice. This occurred in mice harboring either a pan-endothelial Ndst1 mutation or an inducible lymphatic-endothelial specific mutation in Ndst1. In addition to a marked reduction in tumor metastases to the regional lymph nodes in mutant mice, specific immuno-localization of CCL21, a heparin-binding chemokine known to regulate leukocyte and possibly tumor-cell traffic, showed a marked reduction in its ability to associate with tumor cells in mutant lymph nodes. In vitro modified chemotaxis studies targeting heparan sulfate biosynthesis in lymphatic endothelial cells revealed that heparan sulfate secreted by lymphatic endothelium is required for CCL21-dependent directional migration of murine as well as human lung carcinoma cells toward the targeted lymphatic endothelium. Lymphatic heparan sulfate was also required for binding of CCL21 to its receptor CCR7 on tumor cells as well as the activation of migration signaling pathways in tumor cells exposed to lymphatic conditioned medium. Finally, lymphatic cell-surface heparan sulfate facilitated receptor-dependent binding and concentration of CCL21 on the lymphatic endothelium, thereby serving as a mechanism to generate lymphatic chemokine gradients.

Conclusions

This work demonstrates the genetic importance of host lymphatic heparan sulfate in mediating chemokine dependent tumor-cell traffic in the lymphatic microenvironment. The impact on chemokine dependent lymphatic metastasis may guide novel therapeutic strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest. 2009, 136 (1): 260-271. 10.1378/chest.08-0978CrossRefPubMed Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest. 2009, 136 (1): 260-271. 10.1378/chest.08-0978CrossRefPubMed
2.
go back to reference Effenberger KE, Sienel W, Pantel K: Lymph node micrometastases in lung cancer. Cancer Treat Res. 2007, 135: 167-175. full_textCrossRefPubMed Effenberger KE, Sienel W, Pantel K: Lymph node micrometastases in lung cancer. Cancer Treat Res. 2007, 135: 167-175. full_textCrossRefPubMed
3.
go back to reference Perez-Cardona JH, Ordonez NG, Fossella FV: Lymph node micrometastases in non small-cell lung cancer: clinical applications. Clin Lung Cancer. 2000, 2 (2): 116-120. 10.3816/CLC.2000.n.023CrossRefPubMed Perez-Cardona JH, Ordonez NG, Fossella FV: Lymph node micrometastases in non small-cell lung cancer: clinical applications. Clin Lung Cancer. 2000, 2 (2): 116-120. 10.3816/CLC.2000.n.023CrossRefPubMed
4.
go back to reference Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature. 2005, 438 (7070): 946-953. 10.1038/nature04480CrossRefPubMed Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature. 2005, 438 (7070): 946-953. 10.1038/nature04480CrossRefPubMed
5.
go back to reference Cao Y: Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005, 5 (9): 735-743. 10.1038/nrc1693CrossRefPubMed Cao Y: Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005, 5 (9): 735-743. 10.1038/nrc1693CrossRefPubMed
6.
go back to reference Wissmann C, Detmar M: Pathways targeting tumor lymphangiogenesis. Clin Cancer Res. 2006, 12 (23): 6865-6868. 10.1158/1078-0432.CCR-06-1800CrossRefPubMed Wissmann C, Detmar M: Pathways targeting tumor lymphangiogenesis. Clin Cancer Res. 2006, 12 (23): 6865-6868. 10.1158/1078-0432.CCR-06-1800CrossRefPubMed
7.
go back to reference Nathanson SD: Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 98 (2): 413-423. 10.1002/cncr.11464CrossRefPubMed Nathanson SD: Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 98 (2): 413-423. 10.1002/cncr.11464CrossRefPubMed
8.
go back to reference Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA: Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009, 69 (1): 349-357. 10.1158/0008-5472.CAN-08-1875CrossRefPubMed Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA: Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009, 69 (1): 349-357. 10.1158/0008-5472.CAN-08-1875CrossRefPubMed
9.
go back to reference Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, Rigby H, Mortimer PS, Orlando A, Levick JR, Bates DO: Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis. Oncogene. 2007, 26 (21): 2997-3005. 10.1038/sj.onc.1210114CrossRefPubMed Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, Rigby H, Mortimer PS, Orlando A, Levick JR, Bates DO: Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis. Oncogene. 2007, 26 (21): 2997-3005. 10.1038/sj.onc.1210114CrossRefPubMed
10.
go back to reference Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003, 105 (2): 186-189. 10.1002/ijc.11063CrossRefPubMed Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003, 105 (2): 186-189. 10.1002/ijc.11063CrossRefPubMed
11.
go back to reference Maekawa S, Iwasaki A, Shirakusa T, Kawakami T, Yanagisawa J, Tanaka T, Shibaguchi H, Kinugasa T, Kuroki M, Kuroki M: Association between the expression of chemokine receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma. Oncol Rep. 2008, 19 (6): 1461-1468.PubMed Maekawa S, Iwasaki A, Shirakusa T, Kawakami T, Yanagisawa J, Tanaka T, Shibaguchi H, Kinugasa T, Kuroki M, Kuroki M: Association between the expression of chemokine receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma. Oncol Rep. 2008, 19 (6): 1461-1468.PubMed
12.
go back to reference Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res. 2006, 36 (1-3): 61-72. 10.1385/IR:36:1:61CrossRefPubMed Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res. 2006, 36 (1-3): 61-72. 10.1385/IR:36:1:61CrossRefPubMed
13.
go back to reference Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC: Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol. 2005, 6 (9): 889-894. 10.1038/ni1238PubMedCentralCrossRefPubMed Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC: Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol. 2005, 6 (9): 889-894. 10.1038/ni1238PubMedCentralCrossRefPubMed
14.
go back to reference Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT: A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 1998, 95 (1): 258-263. 10.1073/pnas.95.1.258PubMedCentralCrossRefPubMed Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT: A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 1998, 95 (1): 258-263. 10.1073/pnas.95.1.258PubMedCentralCrossRefPubMed
15.
16.
go back to reference Till KJ, Lin K, Zuzel M, Cawley JC: The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002, 99 (8): 2977-2984. 10.1182/blood.V99.8.2977CrossRefPubMed Till KJ, Lin K, Zuzel M, Cawley JC: The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002, 99 (8): 2977-2984. 10.1182/blood.V99.8.2977CrossRefPubMed
17.
go back to reference Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002, 62 (10): 2937-2941.PubMed Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002, 62 (10): 2937-2941.PubMed
18.
go back to reference Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD: A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol. 2005, 174 (3): 1693-1700.PubMedCentralCrossRefPubMed Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD: A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol. 2005, 174 (3): 1693-1700.PubMedCentralCrossRefPubMed
19.
go back to reference Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 2008, 13 (4): 331-342. 10.1016/j.ccr.2008.01.029CrossRefPubMed Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 2008, 13 (4): 331-342. 10.1016/j.ccr.2008.01.029CrossRefPubMed
20.
go back to reference Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL: Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 70 (8): 3042-3051. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL: Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 70 (8): 3042-3051.
21.
go back to reference Ou JJ, Wu F, Liang HJ: Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol Ther. 9 (3): 186-191. Ou JJ, Wu F, Liang HJ: Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol Ther. 9 (3): 186-191.
22.
go back to reference Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007, 446 (7139): 1030-1037. 10.1038/nature05817CrossRefPubMed Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007, 446 (7139): 1030-1037. 10.1038/nature05817CrossRefPubMed
23.
go back to reference Raman K, Kuberan B: Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Curr Chem Biol. 4 (1): 20-31. Raman K, Kuberan B: Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Curr Chem Biol. 4 (1): 20-31.
24.
go back to reference Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell. 2006, 10 (5): 625-634. 10.1016/j.devcel.2006.03.009CrossRefPubMed Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell. 2006, 10 (5): 625-634. 10.1016/j.devcel.2006.03.009CrossRefPubMed
25.
go back to reference Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL: Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 2007, 177 (3): 539-549. 10.1083/jcb.200610086PubMedCentralCrossRefPubMed Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL: Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 2007, 177 (3): 539-549. 10.1083/jcb.200610086PubMedCentralCrossRefPubMed
26.
go back to reference Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE: Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem. 2005, 74: 385-410. 10.1146/annurev.biochem.72.121801.161747CrossRefPubMed Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE: Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem. 2005, 74: 385-410. 10.1146/annurev.biochem.72.121801.161747CrossRefPubMed
27.
go back to reference Rutkowski JM, Boardman KC, Swartz MA: Characterization of lymphangiogenesis in a model of adult skin regeneration. Am J Physiol Heart Circ Physiol. 2006, 291 (3): H1402-1410. 10.1152/ajpheart.00038.2006PubMedCentralCrossRefPubMed Rutkowski JM, Boardman KC, Swartz MA: Characterization of lymphangiogenesis in a model of adult skin regeneration. Am J Physiol Heart Circ Physiol. 2006, 291 (3): H1402-1410. 10.1152/ajpheart.00038.2006PubMedCentralCrossRefPubMed
28.
go back to reference Patel DD, Koopmann W, Imai T, Whichard LP, Yoshie O, Krangel MS: Chemokines have diverse abilities to form solid phase gradients. Clin Immunol. 2001, 99 (1): 43-52. 10.1006/clim.2000.4997CrossRefPubMed Patel DD, Koopmann W, Imai T, Whichard LP, Yoshie O, Krangel MS: Chemokines have diverse abilities to form solid phase gradients. Clin Immunol. 2001, 99 (1): 43-52. 10.1006/clim.2000.4997CrossRefPubMed
29.
go back to reference Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E: Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem. 2007, 282 (13): 10018-10027. 10.1074/jbc.M608796200PubMedCentralCrossRefPubMed Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E: Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem. 2007, 282 (13): 10018-10027. 10.1074/jbc.M608796200PubMedCentralCrossRefPubMed
30.
go back to reference Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H: Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem. 2001, 276 (11): 8288-8296. 10.1074/jbc.M008110200CrossRefPubMed Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H: Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem. 2001, 276 (11): 8288-8296. 10.1074/jbc.M008110200CrossRefPubMed
31.
go back to reference Kuroshima S, Sawa Y, Yamaoka Y, Notani K, Yoshida S, Inoue N: Expression of cys-cys chemokine ligand 21 on human gingival lymphatic vessels. Tissue Cell. 2004, 36 (2): 121-127. 10.1016/j.tice.2003.10.004CrossRefPubMed Kuroshima S, Sawa Y, Yamaoka Y, Notani K, Yoshida S, Inoue N: Expression of cys-cys chemokine ligand 21 on human gingival lymphatic vessels. Tissue Cell. 2004, 36 (2): 121-127. 10.1016/j.tice.2003.10.004CrossRefPubMed
32.
go back to reference Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 2003, 100 (4): 1885-1890. 10.1073/pnas.0334864100PubMedCentralCrossRefPubMed Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH: Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 2003, 100 (4): 1885-1890. 10.1073/pnas.0334864100PubMedCentralCrossRefPubMed
34.
go back to reference Powell AK, Yates EA, Fernig DG, Turnbull JE: Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology. 2004, 14 (4): 17R-30R. 10.1093/glycob/cwh051CrossRefPubMed Powell AK, Yates EA, Fernig DG, Turnbull JE: Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology. 2004, 14 (4): 17R-30R. 10.1093/glycob/cwh051CrossRefPubMed
35.
go back to reference Capila I, Linhardt RJ: Heparin-protein interactions. Angew Chem Int Ed Engl. 2002, 41 (3): 391-412. 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-BCrossRefPubMed Capila I, Linhardt RJ: Heparin-protein interactions. Angew Chem Int Ed Engl. 2002, 41 (3): 391-412. 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-BCrossRefPubMed
36.
go back to reference Desai UR, Wang HM, Linhardt RJ: Substrate specificity of the heparin lyases from Flavobacterium heparinum. Arch Biochem Biophys. 1993, 306 (2): 461-468. 10.1006/abbi.1993.1538CrossRefPubMed Desai UR, Wang HM, Linhardt RJ: Substrate specificity of the heparin lyases from Flavobacterium heparinum. Arch Biochem Biophys. 1993, 306 (2): 461-468. 10.1006/abbi.1993.1538CrossRefPubMed
37.
go back to reference Wang L, Fuster M, Sriramarao P, Esko JD: Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005, 6 (9): 902-910. 10.1038/ni1233CrossRefPubMed Wang L, Fuster M, Sriramarao P, Esko JD: Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005, 6 (9): 902-910. 10.1038/ni1233CrossRefPubMed
38.
go back to reference Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M: Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001, 230 (2): 230-242. 10.1006/dbio.2000.0106CrossRefPubMed Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M: Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001, 230 (2): 230-242. 10.1006/dbio.2000.0106CrossRefPubMed
39.
go back to reference Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 2002, 3 (3): 411-423. 10.1016/S1534-5807(02)00217-4CrossRefPubMed Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 2002, 3 (3): 411-423. 10.1016/S1534-5807(02)00217-4CrossRefPubMed
40.
go back to reference Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, Maekawa H, Kimura Y, Ohmura M, Miyamoto T: Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005, 105 (12): 4649-4656. 10.1182/blood-2004-08-3382CrossRefPubMed Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, Maekawa H, Kimura Y, Ohmura M, Miyamoto T: Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005, 105 (12): 4649-4656. 10.1182/blood-2004-08-3382CrossRefPubMed
41.
go back to reference Soderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, Landegren U: Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008, 45 (3): 227-232. 10.1016/j.ymeth.2008.06.014CrossRefPubMed Soderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, Landegren U: Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008, 45 (3): 227-232. 10.1016/j.ymeth.2008.06.014CrossRefPubMed
42.
go back to reference Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD: HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 2006, 7: 2- 10.1186/1471-2091-7-2PubMedCentralCrossRefPubMed Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD: HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 2006, 7: 2- 10.1186/1471-2091-7-2PubMedCentralCrossRefPubMed
43.
go back to reference Srinivasan RS, Geng X, Yang Y, Wang Y, Mukatira S, Studer M, Porto MP, Lagutin O, Oliver G: The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev. 24 (7): 696-707. Srinivasan RS, Geng X, Yang Y, Wang Y, Mukatira S, Studer M, Porto MP, Lagutin O, Oliver G: The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev. 24 (7): 696-707.
44.
go back to reference de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH: Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol. 2007, 2 (11): 735-744. 10.1021/cb700159mPubMedCentralCrossRefPubMed de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH: Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol. 2007, 2 (11): 735-744. 10.1021/cb700159mPubMedCentralCrossRefPubMed
45.
go back to reference Bobek V, Kolostova K, Pinterov D, Boubelik M, Jiang P, Yang M, Hoffman RM: Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma. Clin Exp Metastasis. 2004, 21 (8): 705-708. 10.1007/s10585-004-8118-8CrossRefPubMed Bobek V, Kolostova K, Pinterov D, Boubelik M, Jiang P, Yang M, Hoffman RM: Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma. Clin Exp Metastasis. 2004, 21 (8): 705-708. 10.1007/s10585-004-8118-8CrossRefPubMed
46.
go back to reference Massena S, Christoffersson G, Hjertstrom E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP, Phillipson M: A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood. 2010, 116 (11): 1924-1931. 10.1182/blood-2010-01-266072PubMedCentralCrossRefPubMed Massena S, Christoffersson G, Hjertstrom E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP, Phillipson M: A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood. 2010, 116 (11): 1924-1931. 10.1182/blood-2010-01-266072PubMedCentralCrossRefPubMed
47.
go back to reference Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H: Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999, 274 (34): 23916-23925. 10.1074/jbc.274.34.23916CrossRefPubMed Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H: Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999, 274 (34): 23916-23925. 10.1074/jbc.274.34.23916CrossRefPubMed
48.
go back to reference Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G: Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004, 15 (3): 603-612. 10.1097/01.ASN.0000113316.52371.2ECrossRefPubMed Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G: Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004, 15 (3): 603-612. 10.1097/01.ASN.0000113316.52371.2ECrossRefPubMed
49.
50.
go back to reference Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G: Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007, 21 (19): 2422-2432. 10.1101/gad.1588407PubMedCentralCrossRefPubMed Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G: Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007, 21 (19): 2422-2432. 10.1101/gad.1588407PubMedCentralCrossRefPubMed
51.
go back to reference Dai E, Liu LY, Wang H, McIvor D, Sun YM, Macaulay C, King E, Munuswamy-Ramanujam G, Bartee MY, Williams J: Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS One. 5 (5): e10510- Dai E, Liu LY, Wang H, McIvor D, Sun YM, Macaulay C, King E, Munuswamy-Ramanujam G, Bartee MY, Williams J: Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS One. 5 (5): e10510-
52.
go back to reference Adhikari N, Basi DL, Townsend D, Rusch M, Mariash A, Mullegama S, Watson A, Larson J, Tan S, Lerman B: Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. J Mol Cell Cardiol. 49 (2): 287-293. Adhikari N, Basi DL, Townsend D, Rusch M, Mariash A, Mullegama S, Watson A, Larson J, Tan S, Lerman B: Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. J Mol Cell Cardiol. 49 (2): 287-293.
53.
go back to reference Bame KJ, Esko JD: Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J Biol Chem. 1989, 264 (14): 8059-8065.PubMed Bame KJ, Esko JD: Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J Biol Chem. 1989, 264 (14): 8059-8065.PubMed
54.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262CrossRefPubMed
55.
go back to reference Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, Cummings RD, Esko JD: Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 2008, 283 (48): 33674-33684. 10.1074/jbc.M804288200PubMedCentralCrossRefPubMed Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, Cummings RD, Esko JD: Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 2008, 283 (48): 33674-33684. 10.1074/jbc.M804288200PubMedCentralCrossRefPubMed
56.
go back to reference Lawrence R, Kuberan B, Lech M, Beeler DL, Rosenberg RD: Mapping critical biological motifs and biosynthetic pathways of heparan sulfate. Glycobiology. 2004, 14 (5): 467-479. 10.1093/glycob/cwh057CrossRefPubMed Lawrence R, Kuberan B, Lech M, Beeler DL, Rosenberg RD: Mapping critical biological motifs and biosynthetic pathways of heparan sulfate. Glycobiology. 2004, 14 (5): 467-479. 10.1093/glycob/cwh057CrossRefPubMed
57.
go back to reference Mancardi S, Stanta G, Dusetti N, Bestagno M, Jussila L, Zweyer M, Lunazzi G, Dumont D, Alitalo K, Burrone OR: Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant. Exp Cell Res. 1999, 246 (2): 368-375. 10.1006/excr.1998.4270CrossRefPubMed Mancardi S, Stanta G, Dusetti N, Bestagno M, Jussila L, Zweyer M, Lunazzi G, Dumont D, Alitalo K, Burrone OR: Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant. Exp Cell Res. 1999, 246 (2): 368-375. 10.1006/excr.1998.4270CrossRefPubMed
58.
go back to reference Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML: VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn. 2006, 235 (12): 3413-3422. 10.1002/dvdy.20982CrossRefPubMed Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML: VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn. 2006, 235 (12): 3413-3422. 10.1002/dvdy.20982CrossRefPubMed
Metadata
Title
A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis
Authors
Xin Yin
Jadwiga Truty
Roger Lawrence
Scott C Johns
R Sathish Srinivasan
Tracy M Handel
Mark M Fuster
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-316

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine